Clearbridge Investments LLC trimmed its holdings in Balchem Co. (NASDAQ:BCPC - Free Report) by 10.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 452,336 shares of the basic materials company's stock after selling 53,807 shares during the quarter. Clearbridge Investments LLC owned approximately 1.40% of Balchem worth $69,637,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. CIBC Asset Management Inc purchased a new stake in shares of Balchem during the 4th quarter worth approximately $289,000. Tower Research Capital LLC TRC boosted its position in Balchem by 543.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 13,676 shares of the basic materials company's stock valued at $2,034,000 after purchasing an additional 11,551 shares in the last quarter. Congress Asset Management Co. MA boosted its position in Balchem by 6.4% during the fourth quarter. Congress Asset Management Co. MA now owns 239,657 shares of the basic materials company's stock valued at $35,649,000 after purchasing an additional 14,354 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Balchem by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 3,791,512 shares of the basic materials company's stock worth $563,987,000 after acquiring an additional 30,868 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Balchem by 18.0% in the first quarter. GAMMA Investing LLC now owns 473 shares of the basic materials company's stock worth $73,000 after acquiring an additional 72 shares in the last quarter. 87.91% of the stock is currently owned by institutional investors.
Insider Transactions at Balchem
In other Balchem news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the company's stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $180.05, for a total transaction of $1,395,387.50. Following the completion of the sale, the senior vice president now directly owns 8,540 shares of the company's stock, valued at approximately $1,537,627. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.25% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on BCPC. StockNews.com cut Balchem from a "buy" rating to a "hold" rating in a research note on Monday, July 29th. HC Wainwright raised their price objective on Balchem from $170.00 to $185.00 and gave the stock a "buy" rating in a research note on Wednesday, July 31st.
Read Our Latest Stock Report on BCPC
Balchem Price Performance
Shares of NASDAQ:BCPC traded down $3.19 during trading on Thursday, reaching $170.97. The stock had a trading volume of 53,109 shares, compared to its average volume of 107,656. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.79 and a current ratio of 2.83. The business has a fifty day moving average price of $171.53 and a 200-day moving average price of $160.34. The stock has a market cap of $5.54 billion, a PE ratio of 48.23, a PEG ratio of 5.54 and a beta of 0.65. Balchem Co. has a 1-year low of $110.74 and a 1-year high of $186.03.
Balchem (NASDAQ:BCPC - Get Free Report) last posted its earnings results on Friday, July 26th. The basic materials company reported $0.98 EPS for the quarter, beating analysts' consensus estimates of $0.95 by $0.03. The company had revenue of $234.08 million for the quarter, compared to the consensus estimate of $241.26 million. Balchem had a return on equity of 10.94% and a net margin of 12.52%. On average, equities analysts forecast that Balchem Co. will post 3.96 earnings per share for the current fiscal year.
Balchem Profile
(
Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Featured Stories
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
